EU Medicines & Pharmacovigilance Regulations, EMA Decisions & Marketing Authorisations
Track Commission implementing decisions on marketing authorisations, EMA CHMP/PRAC opinions, critical medicines shortage prevention, and EU pharmaceutical legislation revisions.
Medicines, Biologicals & Pharmacovigilance Regulatory Landscape & Compliance Overview
Official IntelligencePolicyIndex indexes real-time gazette notifications, policy orders, tariff determinations, and compliance circulars issued across the Medicines, Biologicals & Pharmacovigilance sector. Regulatory intelligence is aggregated across central ministries, state regulatory commissions, and statutory authorities.
Statutory Directives
Official Extraordinary Gazettes, S.O. & G.S.R. orders, and executive notifications.
Compliance Mandates
Sector-specific regulatory obligations, licensing norms, and statutory filing guidelines.
Other Verticals in Healthcare, Pharmaceuticals & Life Sciences
Looking for Weekly Policy & Regulatory Briefings?
Access curated sector roundups, executive summaries, and downloadable PDF intelligence reports.
Official Medicines, Biologicals & Pharmacovigilance Gazettes & Notifications
Frequently Asked Questions on Medicines, Biologicals & Pharmacovigilance Regulations
How does the EU Centralised Procedure for medicines work?
Under Regulation (EC) No 726/2004, the centralised procedure allows pharmaceutical companies to submit a single marketing authorisation application to the EMA. If approved by the European Commission, the authorisation is automatically valid across all 27 EU Member States and EEA countries.
What are the key proposals in the EU Pharmaceutical Legislation Revision?
The revision proposes reducing regulatory data protection periods to incentivise launches in all Member States, faster generic and biosimilar market entry, mandatory supply obligation notifications, environmental risk assessments for manufacturing, transferable exclusivity vouchers for novel antimicrobials (AMR), and a streamlined centralised procedure.
What is the EU Critical Medicines Act and how does it address drug shortages?
The Critical Medicines Act establishes a Union list of critical medicines, mandates supply chain diversification and strategic stockpiling, introduces EU-level shortage monitoring via the EMA, supports domestic API manufacturing through public investment, and requires early warning notifications from marketing authorisation holders.